Anti-DDAH1 antibody [EPR13922]
- RabMAb
- Recombinant
- KO Validated
- What is this?
4
(1 Review)
|
(11 Publications)
Rabbit Recombinant Monoclonal DDAH1 antibody. Suitable for IP, WB, ICC/IF, Flow Cyt (Intra), IHC-P and reacts with Human samples. Cited in 11 publications.
View Alternative Names
DDAH, DDAH1, DDAH-1, Dimethylarginine dimethylaminohydrolase 1, DDAHI, Dimethylargininase-1
- Flow Cyt (Intra)
Unknown
Flow Cytometry (Intracellular) - Anti-DDAH1 antibody [EPR13922] (AB180599)
ab180599 staining DDAH1 in the human cell line 293 (human embryonic kidney) by intracellular flow cytometry. Cells were fixed with 4% paraformaldehyde, permabilised with 90% methanol and the sample was incubated with the primary antibody at a dilution of 1/20. A goat anti rabbit IgG (Alexa Fluor® 488) at a dilution of 1/2000 was used as the secondary antibody.
Isoytype control : Rabbit monoclonal IgG (Black)
Unlabelled control : Cell without incubation with primary antibody and secondary antibody (Blue)
- ICC/IF
Supplier Data
Immunocytochemistry/ Immunofluorescence - Anti-DDAH1 antibody [EPR13922] (AB180599)
Immunofluorescence analysis of 293 cells (fixative 4% paraformaldehyde) labeling DDAH1 with ab180599 at a 1/100 dilution (left image), and counterstained with Dapi (right image). Goat anti rabbit IgG (Dylight 555) secondary used at a 1/200 diution.
- IHC-P
Supplier Data
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-DDAH1 antibody [EPR13922] (AB180599)
Immunohistochemical analysis of paraffin embedded Human ovarian carcinoma tissue labeling DDAH1 with ab180599 at a 1/50 dilution. Prediluted HRP Polymer for Rabbit IgG secondary used. Counterstained with Hematoxylin.
Perform heat mediated antigen retrieval with EDTA buffer pH 9 before commencing with IHC staining protocol.
- IP
Supplier Data
Immunoprecipitation - Anti-DDAH1 antibody [EPR13922] (AB180599)
Immunoprecipitation analysis of Human fetal kidney lysate labeling DDAH1 with ab180599 at a 1/40 dilution. Goat Anti-Rabbit IgG (H+L) Peroxidase conjugated secondary used at a 1/1000 dilution.
All lanes:
Immunoprecipitation - Anti-DDAH1 antibody [EPR13922] (ab180599)
Predicted band size: 31 kDa
false
- WB
Lab
Western blot - Anti-DDAH1 antibody [EPR13922] (AB180599)
Lanes 1 - 4 : Merged signal (red and green). Green - ab180599 observed at 37 kDa. Red - loading control, ab7291 (Mouse anti-Alpha Tubulin [DM1A] observed at 55kDa.
ab180599 was shown to react with DDAH1 in A431 wild-type cells in Western blot. Loss of signal was observed when DDAH1 knockout sample was used. A431 wild-type and DDAH1 knockout cell lysates were subjected to SDS-PAGE. Membranes were blocked in 3% Milk in TBS-T (0.1% Tween®) before incubation with ab180599 and ab7291 (Mouse anti-Alpha Tubulin [DM1A] overnight at 4°C at a 1 in 10000 dilution and a 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.
All lanes:
Western blot - Anti-DDAH1 antibody [EPR13922] (ab180599) at 1/10000 dilution
Lane 1:
Wild-type A431 cell lysate at 40 µg
Lane 2:
Western blot - Human DDAH1 knockout A-431 cell lysate (<a href='/en-us/products/cell-lysates/human-ddah1-knockout-a-431-cell-lysate-ab261715'>ab261715</a>) at 40 µg
Lane 3:
HUVEC (Human umbilical vein endothelial cell line) whole cell lysate at 40 µg
Lane 4:
HepG2 (Human liver hepatocellular carcinoma cell line) whole cell lysate at 40 µg
Secondary
Lanes 1 - 4:
Western blot - Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-irdye-800cw-preadsorbed-ab216773'>ab216773</a>) at 1/20000 dilution
Lanes 1 - 4:
Western blot - Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (<a href='/en-us/products/secondary-antibodies/goat-mouse-igg-h-l-irdye-680rd-preadsorbed-ab216776'>ab216776</a>) at 1/20000 dilution
Predicted band size: 31 kDa
Observed band size: 37 kDa,55 kDa
false
- WB
Supplier Data
Western blot - Anti-DDAH1 antibody [EPR13922] (AB180599)
All lanes:
Western blot - Anti-DDAH1 antibody [EPR13922] (ab180599) at 1/20000 dilution
Lane 1:
Human fetal brain lysate at 20 µg
Lane 2:
Human fetal liver lysate at 20 µg
Lane 3:
Human fetal kidney lysate at 20 µg
Lane 4:
293 lysate at 10 µg
Secondary
All lanes:
Goat Anti-Rabbit IgG (H+L) Peroxidase conjugated at 1/1000 dilution
Predicted band size: 31 kDa
Observed band size: 37 kDa
false
Related conjugates and formulations (10)
-
Anti-DDAH1 antibody [EPR13922] - BSA and Azide free
-
578 PE
PE Anti-DDAH1 antibody [EPR13922]
-
660 APC
APC Anti-DDAH1 antibody [EPR13922]
-
519 Alexa Fluor® 488
Alexa Fluor® 488 Anti-DDAH1 antibody [EPR13922]
-
665 Alexa Fluor® 647
Alexa Fluor® 647 Anti-DDAH1 antibody [EPR13922]
-
603 Alexa Fluor® 568
Alexa Fluor® 568 Anti-DDAH1 antibody [EPR13922]
-
HRP Anti-DDAH1 antibody [EPR13922]
-
617 Alexa Fluor® 594
Alexa Fluor® 594 Anti-DDAH1 antibody [EPR13922]
-
565 Alexa Fluor® 555
Alexa Fluor® 555 Anti-DDAH1 antibody [EPR13922]
-
775 Alexa Fluor® 750
Alexa Fluor® 750 Anti-DDAH1 antibody [EPR13922]
Reactivity data
Product details
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
Properties and storage information
Form
Purification technique
Storage buffer
Shipped at conditions
Appropriate short-term storage duration
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Aliquoting information
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
The actions of DDAH1 contribute significantly to cardiovascular homeostasis. Increased levels of ADMA resulting from impaired DDAH1 activity can lead to decreased NO production impacting cardiovascular health. DDAH1 does not form part of a complex but acts individually to affect NO synthesis through ADMA degradation. Understanding the biological roles of DDAH1 helps to appreciate how NO-mediated processes are tightly regulated within the body and its impact on vascular health.
Pathways
DDAH1 participates actively in the nitric oxide synthesis pathway. It modulates the levels of endothelial nitric oxide synthase (eNOS) by regulating ADMA which serves as an eNOS inhibitor. Through this pathway DDAH1 ensures a balance between NO production and regulation supporting vascular homeostasis and blood pressure control. DDAH1 shares functional connections with proteins like eNOS which are central to maintaining vascular health and preventing endothelial dysfunction.
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Publications (11)
Recent publications for all applications. Explore the full list and refine your search
Cell death & disease 15:399 PubMed38849335
2024
Applications
Unspecified application
Species
Unspecified reactive species
Regenerative therapy 27:398-407 PubMed38694446
2024
Applications
Unspecified application
Species
Unspecified reactive species
International journal of molecular sciences 22: PubMed34830164
2021
Applications
Unspecified application
Species
Unspecified reactive species
iScience 24:103189 PubMed34703990
2021
Applications
Unspecified application
Species
Unspecified reactive species
Glia 69:2591-2604 PubMed34270117
2021
Applications
Unspecified application
Species
Unspecified reactive species
Frontiers in cardiovascular medicine 7:615161 PubMed33365332
2020
Applications
Unspecified application
Species
Unspecified reactive species
Journal of cellular and molecular medicine 24:5911-5925 PubMed32301289
2020
Applications
Unspecified application
Species
Unspecified reactive species
Clinical and experimental pharmacology & physiolog 47:1182-1192 PubMed32020664
2020
Applications
Unspecified application
Species
Unspecified reactive species
Nitric oxide : biology and chemistry 93:44-52 PubMed31536826
2019
Applications
Unspecified application
Species
Unspecified reactive species
Experimental biology and medicine (Maywood, N.J.) 243:934-944 PubMed29984607
2018
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com